|
KMID : 0371320020630040283
|
|
Journal of the Korean Surgical Society
2002 Volume.63 No. 4 p.283 ~ p.286
|
|
|
Comparison of Tamoxifen and Toremifene as Adjuvant Treatment in Node-negative Postmenopausal Breast Cancer
|
|
Han Se-Hwan
Yang Keun-Ho
Bae Byung-Noe
Kim Ki-Whan
Kim Hong-Joo
Kim Young-Duck
Kim Hong-Yong
|
|
|
Abstract
|
|
|
Purpose: To evaluate the differences in therapeutic efficacy and toxicity profiles between adjuvant toremifene and tamoxifene in postmenopausal breast cancer patients.
Methods: Toremifene 40 ㎎ (n=115) and tamoxifen 20 ㎎ (n =116) were administered daily for more than 2 years after curative surgery for lymph node-negative breast cancer. Toxicity profiles were compared between the two groups and the
patient
survival rate was also analyzed.
Results: Sweating and hot flashes were the most common symptoms in the two groups (toremifene vs. tamoxifen= 47.8% vs. 49.1%). Increase of vaginal discharge (39.1% vs. 36.2%) and weight gain (21.7% vs. 24.1%) were the next following
adverse
effects. There was no significant difference in adverse effect between the two groups. During the median follow-up period of 25 months (range: 9∼38 months), five (4.3%) and four (3.3%) patients treated by toremifene and tamoxifen, respectively,
had
recurrent disease.
Conclusion: The clinical outcome and adverse effect profiles of toremifene were similar to those of tamoxifen. Toremifene at 40 ㎎/day seems to be as safe and effective as tamoxifen at 20 ㎎/day in the treatment of postmenopausal,
node-negative,
breast cancer. However, a longer follow-up study is needed to verify this.
|
|
|
KEYWORD
|
|
|
|
|
|
FullTexts / Linksout information
|
|
  
|
|
|
Listed journal information
|
|
  
|